- Le evidenze mostrano che il raggiungimento del 90% del miglioramento del Psoriasis Area and Severity Index score (PASI90) ha una miglior correlazione con l’Health-related quality of life rispetto al PASI75; pertanto, vi è una maggior richiesta di determinare nuovi obiettivi terapeutici per la psoriasi.
- Secondo il presente studio, il raggiungimento del PASI90 a breve termine è un miglior fattore prognostico di una più lunga aderenza terapeutica rispetto al raggiungimento del PASI75.
With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved health-related quality of life as compared to PASI75 achievement, there has been demand for establishing new treatment goals for psoriasis. We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
This single-center retrospective cohort study reviewed 180 treatment series in 128 patients with plaque psoriasis, who were treated with tumor necrosis factor-alpha inhibitors (n = 12), ustekinumab (n = 88), secukinumab (n = 23), guselkumab (n = 45), and ixekizumab (n = 12). The first effectiveness assessment, usually performed within 12 to 20 weeks, was considered a short-term treatment response to biologics.
After adjustment for covariates, time-dependent Cox proportional hazards regression analysis showed that moderate responders (short-term achievement of ≥PASI75 but <PASI90) were more likely to discontinue therapy than the excellent responders (short-term achievement of PASI90; adjusted hazard ratio, 3.159; 95% confidence interval, 1.180~8.457; p = 0.0220).
The short-term PASI90 achievement is a better predictor of longer drug survival as compared to PASI75 achievement.